Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN entered into an exclusive licensing agreement with Tesaro, Inc., a subsidiary of GSK, for the development and commercialization of a subcutaneous (SC) formulation of GSK’s anticancer treatment dostarlimab using ALT-B4 technology. The deal is valued at up to USD 285M (approx. KRW 420B), including an upfront payment of approx. KRW 29.5B.
📊 [Key Disclosure Details & Major Figures Summary]
- Contract Counterparty: Tesaro, Inc. (USA, subsidiary of GSK plc)
- Contract Details: Exclusive license for the development and commercialization of a subcutaneous formulation of GSK’s anticancer drug dostarlimab using ALTEOGEN’s Hybrozyme-platform-based human hyaluronidase (ALT-B4)
- Execution Date / Contract Term: January 20, 2026 / Until the expiration of the royalty period
- Financial Details:
- Upfront Payment: USD 20,000,000 (Approx. KRW 29.5B based on FX rate 1,473.60 KRW/USD)
- Equivalent to approx. 28.7% of FY2024 consolidated revenue (KRW 102.9B)
- Expected receipt within 10 business days from execution date (by February 03, 2026)
- Milestone Payments: USD 265,000,000 (Approx. KRW 390.5B) based on clinical, regulatory, and commercial milestones
- Maximum Total Contract Value (Upfront + Milestones): USD 285,000,000 (Approx. KRW 420.0B)
- Sales Royalties: Royalties based on a percentage of net sales following commercial launch (separate)
- Upfront Payment: USD 20,000,000 (Approx. KRW 29.5B based on FX rate 1,473.60 KRW/USD)
- Investment Risks & Precautionary Notes:
- Upfront, milestone, and royalty payments received are non-refundable
- Conditional contract subject to regulatory approvals; may be reduced or terminated in the event of clinical trial failure or counterparty termination
- Disclosure Deferral: Specific milestone/royalty breakdowns deferred due to confidentiality obligations
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Upfront Payment Receipt and Milestone Progress
This disclosure formally announces an exclusive licensing agreement for ALT-B4 technology. Verifying the receipt of the upfront payment (approx. KRW 29.5B) by the scheduled date (February 03, 2026) and tracking subsequent clinical and regulatory milestone achievements for the dostarlimab SC formulation is essential because it allows investors to confirm the execution and financial realization of the technology transfer. Detailed updates can be cross-checked in subsequent periodic reports (Quarterly, Half-Yearly, and Annual Reports) and related disclosure filings.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
